The Division of Research Administration and Industry Ventures is composed of multiple departments that work closely together to enable research collaborations between MD Anderson and industry. From internal approval processes for contract execution and grant submission, to intellectual property management and strategic business development, the division helps facilitate strategic partnership opportunities on behalf of the institution.
How We Partner with Industry
Strategic Alliances
Strategic alliances aim to provide space for innovative collaborations to accelerate breakthrough discoveries in cancer research. Our goal at the Office of Strategic Industry Ventures is to develop deeper and more robust relationships with companies that share a similar vision and goal.
Technology Commercialization
Technology transfer aims to transition institutional intellectual property to third parties for further development and commercialization. We cultivate relationships with reputable entities and entrepreneurs with a proven record of advancing technologies to the market.
Creative Solutions
The Office of Strategic Industry Ventures and Office of Technology Commercialization teams collaborate routinely to align interests and goals with stakeholders to deliver innovative pathways and contractual frameworks to partner with industry.
Highlights
MD Anderson and Summit Therapeutics announce strategic collaboration to accelerate development of ivonescimab
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.
Leveraging MD Anderson’s clinical infrastructure and research expertise together with Summit’s innovative, investigational, potential first-in-class PD-1/VEGF bispecific antibody, the collaboration is designed to quickly discover additional opportunities for ivonescimab, including several tumors outside of its current development plan. MD Anderson will lead multiple clinical trials in several tumor types to evaluate the safety and potential clinical benefit of ivonescimab, including the possibility of identifying biomarkers through additional research activities.
“We are excited to collaborate with MD Anderson to provide unique insights and expertise to further broaden the development of ivonescimab,” said Allen S. Yang, M.D., Ph.D., chief medical officer of Summit. “This collaboration will help accelerate the growing clinical development efforts for ivonescimab and help bring this innovative advancement on immunotherapy and anti-angiogenic standards to as many patients who may benefit as possible.”
Early work may include certain types of renal cell carcinoma, colorectal cancer, skin cancer, breast cancer and glioblastoma, which has the potential to rapidly expand the breadth and depth of the ivonescimab development program. The bispecific antibody has shown significant promise in recent read-outs from the randomized Phase III non-small cell lung cancer clinical trials, HARMONi-A and HARMONi-2, conducted by Summit’s partner, Akeso, in addition to promising Phase II data in other solid tumors.
“Through our extensive clinical research efforts, we are committed to bringing impactful new medicines to patients in need as rapidly as possible,” said Christopher Flowers, M.D., division head of Cancer Medicine at MD Anderson. “We are pleased to be collaborating with Summit to broaden the clinical development efforts of ivonescimab and its unique mechanism of action to support our mutual goal to improve the therapeutic options for patients with cancer.”
MD Anderson and Summit will collaborate on the design and conduct of preclinical and clinical studies, with oversight from a joint steering committee. This research is expected to begin later this year.
MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, and manufacturing and MD Anderson’s expertise in cancer antigen discovery and validation, translational drug development, and clinical research. The collaboration will focus on the development of differentiated cancer vaccine candidates in selected hematological and solid tumor indications with high unmet medical need.
"We look forward to collaborating with the team at MD Anderson to push the boundaries of mRNA technology and develop impactful therapeutic options for patients in need," said Alexander Zehnder, M.D., chief executive officer of CureVac. “In combining our respective expertise, we believe we can go further and faster to develop novel, off-the-shelf, mRNA-based cancer vaccines that have the potential to significantly improve patient outcomes.”
Both parties will contribute to the identification of differentiated cancer antigens based on whole genome sequencing combined with long- and short-read RNA sequencing and cutting-edge bioinformatics. Joint preclinical validation of the highest-quality cancer antigens will be supported by Sachet Shukla, Ph.D., assistant professor of Hematopoietic Biology and Malignancy and director of the department’s cancer vaccine program, and by MD Anderson’s ECLIPSE (Evolution of Cancer, Leukemia, and Immunity Post Stem cEll transplant) platform, part of the institution’s Therapeutics Discovery division.
“We are excited for cancer vaccines to potentially emerge as an essential therapeutic tool in the future,” Shukla said. “This collaboration with CureVac is an important milestone in our efforts and brings together complementary strengths toward our goal of developing transformative vaccines for cancer.”
Following selection of the most promising clinical-lead vaccine candidates and completion of Investigational New Drug (IND) approvals, MD Anderson will be responsible for conducting initial Phase I/II studies in appropriate clinical indications.
“Our ECLIPSE team uses proprietary high-throughput technology to identify and validate immune targets, and we are driven to advance impactful immunotherapies with the potential to transform the lives of patients with cancer,” said Jeffrey Molldrem, M.D., chair of Hematopoietic Biology and Malignancy and leader of the ECLIPSE platform at MD Anderson. “Together with CureVac, we hope to embrace this exciting area of drug discovery and development in pursuit of mRNA vaccines that will address significant unmet medical need.”
Under the terms of the collaboration agreement, CureVac and MD Anderson will jointly contribute to and support development of those programs designated to move forward. CureVac has worldwide exclusive rights to late-stage development, commercialization, or partnering of the cancer vaccine candidates. MD Anderson is eligible for certain downstream payments based on potential future commercialization.
Contact Us
Email our teams to learn more.